Download PDF
Semin Respir Crit Care Med 2001; 22(1): 051-060
DOI: 10.1055/s-2001-13840
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Controversies in the Antibiotic Management of Critically Ill Patients

Jean M. Carlet
  • Fondation-Hopital Saint-Joseph, Paris, France
Further Information

Publication History

Publication Date:
31 December 2001 (online)

    Permissions and Reprints

ABSTRACT

Preventing infection, managing antibiotics, and controlling antibiotic resistance are integral to the daily practice of any physician caring for critically ill patients. Many controversies remain in this area, but improving our ability to manage anti-infective drugs is likely to be a determinant factor on the outcome of critically ill patients. Several measures to prevent nosocomial infections are available, including selective digestive decontamination (SDD) and antibiotic-coated catheters, but a careful assessment of the effect of these strategies upon resistance is needed before considering their extensive use in the ICU. Antibiotic therapy of severely infected patients can be considered as a two-step contract, the first part of which consists in providing individual patients with the best antibiotic strategy. This raises important, although often unsolved, questions regarding the dose, the interest of combining two antibiotics, and the length of therapy. The second part of the contract concerns not only individual patients but the community. Reassessment of the initial therapy is mandatory to avoid prolonged and unnecessary usage of broad spectrum and costly antibiotics, which increase resistance pressure. In many cases, antibiotics can be either stopped or changed after 2 or 3 days.

KEYWORD

Severe infection - antibiotics - intensive care - selective digestive decontamination (sdd) - pharmacokinetics - antibiotic resistance

REFERENCES

  • 1 Brun-Buisson C, Doyon C, Carlet J. Incidence risk factors and outcome of severe sepsis and septic shock in adults: a multicenter prospective study in intensive care units.  JAMA . 1995;  274 968-974
    CrossrefPubMedGoogle Scholar
  • 2 Brun-Buisson C, Doyon C, Carlet J. Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals.  Am J Resp Crit Care Med . 1996;  154 617-624
    PubMedGoogle Scholar
  • 3 Pittet D, Wenzel R P. Nosocomial bloodstream infections: secular trends in rates, mortality, and contribution to total hospitals deaths.  Arch Intern Med . 1995;  155 1177-1184
    CrossrefPubMedGoogle Scholar
  • 4 Rangel Frausto S, Pittet D, Tamara D. SIRS, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients.  Intensive Care Med . 1995;  21 302-309
    CrossrefPubMedGoogle Scholar
  • 5 Vincent J, Bihari D, Ster P. The prevalence of nosocomial infection in intensive care units in Europe: results of the European prevalence of infection in intensive care (EPIC) study.  JAMA . 1995;  274 639-644
    CrossrefPubMedGoogle Scholar
  • 6 Alvarez-Lema F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit.  Intensive Care Med . 1996;  22 683-687
    PubMedGoogle Scholar
  • 7 Ibrahim E H, Ward S, Sherman G, Kollef M H. The influence of inadequate antimicrobial treatment of bloodstream infections on patients outcomes in the ICU setting.  Chest . 2000;  118 146-155
    CrossrefPubMedGoogle Scholar
  • 8 Kunin C. Resistance to antimicrobial drugs: a worldwide calamity.  Ann Intern Med . 1993;  118 557-561
    PubMedGoogle Scholar
  • 9 Gold H S, Moellering R C. Antimicrobial-drug resistance.  N Engl J Med . 1996;  335 1445-1453
    CrossrefPubMedGoogle Scholar
  • 10 Goldman D, Weistein R, Wenzel R. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in the hospitals: a challenge to hospital leadership.  JAMA . 1996;  275 234-240
    CrossrefPubMedGoogle Scholar
  • 11 Mainardi J L, Carlet J, Acar J. Antibiotic resistance problems in the critical care unit.  Crit Care Clin . 1998;  14 199-219
    CrossrefPubMedGoogle Scholar
  • 12 Murray B. Vancomycin-resistant enterococcal infections.  New Engl J Med . 2000;  342 710-721
    CrossrefPubMedGoogle Scholar
  • 13 Hiramatsu K, Aritaka N, Hanaki H. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.  Lancet . 1997;  350 1670-1673
    CrossrefPubMedGoogle Scholar
  • 14 Raad I, Darouiche R, Dupuis J. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections.  Ann Intern Med . 1997;  127 267-274
    PubMedGoogle Scholar
  • 15 Darouiche R, Raad I, Heard S. A comparison of two antimicrobial-impregnated central venous catheters.  New Engl J Med . 1999;  340 1-8
    CrossrefPubMedGoogle Scholar
  • 16 Stoutenbeek C P, van Saene K F H, Miranda D R, Zandstra D F, Langrehr D. The effect of oropharyngeal decontamination using topical nonabsorbable antibiotics on the incidence of nosocomial respiratory tract infections in multiple trauma patients.  J Trauma . 1987;  27 357-364
    PubMedGoogle Scholar
  • 17 Stoutenbeek C P, van Saene K F H, Miranda D R, Zandstra D F, Langrehr D. Nosocomial gram-negative pneumonia in critically ill patients: a 3-year experience with a novel therapeutic regimen.  Intensive Care Med . 1986;  12 419-423
    PubMedGoogle Scholar
  • 18 Loirat P, Bauernfeind A, Binslev A, Falke K, Finch R G, Launois R, Reynart M, Robotham J L, Tognoni G, Torres A, van der Meer W M J. First European consensus conference in intensive care medicine: selective digestive decontamination in intensive care unit patients.  Intensive Care Med . 1992;  18 182-188
    CrossrefPubMedGoogle Scholar
  • 19 Selective Decontamination of the Digestive Tract Trialists' Collaborative Group. Meta-analysis of randomized controlled trials of selective decontamination of the digestive tract.  Br Med J . 1993;  307 525-532
    PubMedGoogle Scholar
  • 20 D'Amico R, Pifferi S, Leonetti C, Torri V, Tinazzi A, Liberati A. Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomised controlled trials.  Br Med J . 1998;  316 1275-1285
    PubMedGoogle Scholar
  • 21 Nathens A B, Marshall J C. Selective decontamination of the digestive tract in surgical patients: a systematic review of the evidence.  Arch Surg . 1999;  134 170-176
    PubMedGoogle Scholar
  • 22 Gastinne H, Wolff M, Lachatre G, Boiteau R, Savy F P. Antibiotic levels in bronchial tree and in serum during selective digestive decontamination.  Intensive Care Med . 1991;  17 215-218
    PubMedGoogle Scholar
  • 23 Sirvent J M, Torres A, El Ebiary M, Castro P, de Batlle J, Bonet A. Protective effect of intravenously administered cefuroxime against nosocomial pneumonia in patients with structural coma.  Am J Respir Crit Care Med . 1997;  155 1729-1734
    PubMedGoogle Scholar
  • 24 Misset B, Artigas A, Bihari D, Carlet J, Durocher A, Hemmer M, Langer M, Nicolas F, De Rohan-Chabot P, Schuster H P, Tenaillon A. Short-term impact of the European consensus conference on the use of selective decontamination of the digestive tract with antibiotics in ICU patients.  Intensive Care Med . 1996;  22 981-984
    CrossrefPubMedGoogle Scholar
  • 25 Wunderink R G. Attributable mortality of ventilator associated pneumonia.  Sepsis . 1998;  1 211-221
    CrossrefPubMedGoogle Scholar
  • 26 Carlet J, Timsit J F, Misset B, Garrouste M, Soufir L. Mortality and Morbidity of Ventilator Associated Pneumonia: The Controversy in ``Nosocomial Pneumonia in ICU Patients''. Kluwer Academic; in press. W. Wunderink and J. Rello Edits
    Google Scholar
  • 27 Kollef M H, Silver P, Murphy D H. The effect of late onset ventilator associated pneumonia in determining patient mortality.  Chest . 1995;  108 1655-1662
    CrossrefPubMedGoogle Scholar
  • 28 Stoutenbeek C P, Van Saene K F H, Zandstra D F. The effect of oral non-absorbable antibiotics on the emergence of resistant bacteria in patients in an intensive care unit.  J Antimibrob Chemother . 1987;  19 513-520
    PubMedGoogle Scholar
  • 29 Unertl K, Ruckdeschel G, Selbmann H K. Prevention of colonization and respiratory infections in long-term ventilated patients by local antimicrobial prophylaxis.  Intensive Care Med . 1987;  13 106-113
    PubMedGoogle Scholar
  • 30 Nardi G, Valentinis U, Proietti A. Epidemiological impact of prolonged systematic use of topical SDD on bacterial colonization of the tracheobronchial tree and antibiotic resistance: a three-year study.  Intensive Care Med . 1933;  19 273-278
    PubMedGoogle Scholar
  • 31 Lingnau W, Berger J, Javorsky F, Fille M, Allerberger F, Benzer H. Changing bacterial ecology during a five-year period of selective intestinal decontamination.  J Hospital Infection . 1988;  39 195-206
    PubMedGoogle Scholar
  • 32 Verwaest C, Verhaegen J, Ferdinande P, Schetz M, Van Den berghe G, Verbist L, Lauwers P. Randomized, controlled trial of selective digestive decontamination in 600 mechanically ventilated patients in a multidisciplinary intensive care unit.  Crit Care Med . 1997;  25 63-71
    CrossrefPubMedGoogle Scholar
  • 33 Bonten M, Van Tiel F, Van Der Geest S. Enterococcus faecalis pneumonia complicating topical antimicrobial prophylaxis.  N Engl J Med . 1992;  328 209-210
    PubMedGoogle Scholar
  • 34 Misset B, Kitzis M D, Mahe P, Conscience G, Goldstein F W, Fourrier A, Carlet J. Bacteriological side effects of gut decontamination with polymyxin E, gentamicin and amphotericin B on fecal flora in general ICU patients.  Inf Control Hospit Epid . 1993;  14 62-64
    PubMedGoogle Scholar
  • 35 Misset B, Kitzis M D, Conscience G, Goldstein F W, Fourrier A, Carlet J. Mechanisms of failure to decontaminate the gut with polymyxin E, gentamicin and amphotericin B in patients in intensive care.  Eur J Clin Microbiol Infect Dis . 1994;  13 165-170
    PubMedGoogle Scholar
  • 36 Moore R, Smith C, Lietman P. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.  J Infect Dis . 1984;  149 443-448
    CrossrefPubMedGoogle Scholar
  • 37 Forrest A, Nix D, Ballow C. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.  Antimicrob Agents Chemother . 1993;  37 1073-1089
    CrossrefPubMedGoogle Scholar
  • 38 Fink M, Snydman D, Niederman M. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intra-venous ciprofloxacin with imipenem-cilastatin.  Antimicrob Agents Chemother . 1994;  38 547-557
    CrossrefPubMedGoogle Scholar
  • 39 Caldwell J W, Singh S, Johnson R H. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia.  J Antimicrob Chemother . 1999;  43 115
    CrossrefPubMedGoogle Scholar
  • 40 Krumpe P E, Cohn S, Garreltes J, Ramirez J, Coulter H, Haverstock D, Echols R. Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group.  J Antimicrob Chemother . 1999;  43 117-128
    PubMedGoogle Scholar
  • 41 Georges B, Archambaud M, Saivin S, Decun J F, Cougot P, Mazerolles M, Andrieu P, Suc C, Houin G, Chabanon G, Virenque C. Continuous versus intermittent cefepime infusion in critical care: preliminary results.  Pathol Biol . 1999;  47 483-485
    PubMedGoogle Scholar
  • 42 Conil J M, Favarel H, Laguerre J. Continuous administration of vancomycin in patients with severe burns.  Presse Med . 1994;  23 1554-1558
    PubMedGoogle Scholar
  • 43 Fayed D F, Dahmash N S, al-Zeer A H. Efficacy and safety of once-daily amikacin in combination with ceftazidime in critically ill adults with severe gram-negative infections.  J Chemother . 1996;  8 457-464
    PubMedGoogle Scholar
  • 44 Solomkin J, Reinhard H, Dellinger E. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/ cilastatin for intra-abdominal infections: the intra-abdominal infection study group.  Ann Surg . 1996;  223 303-315
    CrossrefPubMedGoogle Scholar
  • 45 Brismar B, Malmborg A, Tunevall G. Piperacillin-tazobactam versus imipenem-cilastatin in the treatment of intra-abdominal infections.  Antimicrob Agents Chemother . 1992;  36 2766-3773
    PubMedGoogle Scholar
  • 46 Roosendaal R, Bakker-Woudenberg I, van den Bergvan Raffe M. Comparative activities of ciprofloxacin and ceftazidime against klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats.  Antimicrob Agents Chemother . 1987;  31 1809-1815
    PubMedGoogle Scholar
  • 47 Beaucaire G, Nicolas M H, Martin C, Offenstadt G, Philippon A, Holzapfel L, Pean Y, Leophonte P, Le Fur D, Renard S. PHARE study. Comparative study of combined cefepime-amikacin versus ceftazidime combined with amikacin in the treatment of nosocomial pneumonias in ventilated patients: multicenter group study.  Ann Fr Anesth Reanim . 1999;  18 186-195
    PubMedGoogle Scholar
  • 48 Fagon J, Patrick H, Haas D W, Torres A, Gibert C, Cheadle W G, Falcone R E, Anholm J D, Paganin F, Fabian T C, Lilienthal F. Treatment of gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.  Am J Respir Crit Care Med . 2000;  161 753-762
    CrossrefPubMedGoogle Scholar
  • 49 Brun-Buisson C, Sollet J P, Schweich H, Briere S, Petit C. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group.  Clin Infect Dis . 1998;  26 346-354
    CrossrefPubMedGoogle Scholar
  • 50 Michea-Hamzepour M, Auckenthaler R, Regamey P, Pechere J. Resistance occuring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis.  Antimicrob Agents Chemother . 1987;  31 1803-1808
    PubMedGoogle Scholar
  • 51 Glauser M, Bootgaerts M, Cordonnier C, Palmblad J, Martino P. Empiric therapy of bacterial infections in severe neutropenia.  Clin Microbiol Infect . 1997;  3 S77-S86
    PubMedGoogle Scholar
  • 52 Montravers P, Gauzit R, Muller C, Marmuse J, Fichelle A, Desmonts J. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intra-abdominal surgery affects the efficacy of empirical therapy.  Clin Infect Dis . 1996;  23 486-494
    CrossrefPubMedGoogle Scholar
  • 53 Cometta A, Baumgartner J, Lew D. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients.  Antimicrob Agents Chemother . 1994;  38 1309-1313
    CrossrefPubMedGoogle Scholar
  • 54 Dupont H, Carbon C, Carlet J, and the Severe Generalized Peritonitis Study Group. Monotherapy with piperacillin plus tazobactamis as effective as the combination of piperacillin plus tazobactam and an aminoglycoside (amikacin) in the treatment of severe generalized peritonitis.  Antimicrobial Agents Chemother . 2000;  44 2025-2033
    PubMedGoogle Scholar
  • 55 Fein A, Niederman M. Guidelines for the initial management of community-acquired pneumonia: savory recipe or cookbook for disaster?.  Am J Resp Crit Care Med . 1995;  152 1149-1153
    PubMedGoogle Scholar
  • 56 American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies: a consensus statement.  Am J Resp Crit Care Med . 1996;  123 1711-1725
    PubMedGoogle Scholar
  • 57 Carmeli Y, Troillet N, Eliopoulos G, Samore M. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents.  Antimicrob Agents Chemother . 1999;  43 1379-1382
    PubMedGoogle Scholar
  • 58 Mebis J, Goossens H, Bruyneel P. Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients.  Leukomia . 1998;  12 1627-1629
    PubMedGoogle Scholar
  • 59 Struelens M J, Byl B, Govaerts D. Modification of antibiotic policy associated with decrease in antibiotic-resistant gram-negative bacilli in intensive care units. (Abstract K-12) In: Programs and Abstracts of the 38th Interscience Conference on Antimicrobial Agents Chemotherapy San Diego, CA; Washington, DC: American Society for Microbiology 1998: 502
    Google Scholar
  • 60 Eng R HK, Smith S M, Fan-Hvard P. Effects of antibiotics on endotoxin release from gram-negative bacteria.  Diagn Microbiol Infect Dis . 1993;  16 185-189
    CrossrefPubMedGoogle Scholar
  • 61 Maury E, Barakett V, Blanchard H, Guitton C, Fitting C, Vassal T, Chauvin P, Guidet B, Offenstadt G. Circulating endotoxin during initial antibiotic treatment of severe gram-negative bacteremic infections.  J Infect Dis . 1998;  178 270-273
    PubMedGoogle Scholar
  • 62 Garau J, Wilson W, Wood M, Carlet J. Fourth-generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility.  Clin Microbiol Infect . 1997;  3 S87-S101
    PubMedGoogle Scholar
  • 63 Kollef M H, Vlasnik J, Sharpless L. Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia.  Am J Respir Crit Care Med . 1997;  156 1040-1048
    PubMedGoogle Scholar
  • 64 Niederman M S. Is ``crop rotation'' of antibiotics the solution to a ``resistant'' problem in the ICU?.  Am J Respir Crit Care Med . 1997;  156 1029-1031
    PubMedGoogle Scholar
  • 65 John Jr F J. Antibiotic cycling: is it ready for prime time?.  Infect Control Hosp Epidemiol . 2000;  21 9-11
    PubMedGoogle Scholar
  • 66 Mc Gowan Jr E J. Strategies for study of the role of cycling on antimicrobial use and resistance.  Infect Control Hosp Epidemiol . 2000;  21 S36-S43
    PubMedGoogle Scholar
  • 67 Mc Gowan J. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance?.  Infect Control Hosp Epidemiol . 1994;  15 478-483
    PubMedGoogle Scholar
  • 68 Niederman M S, Bass J B, Campbell G D. Guidelines for the initial management of adults with community acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy.  Am J Resp Crit Care Med . 1993;  148 1418-1426
    PubMedGoogle Scholar
  • 69 Natsh S, Kullberg B J, Meis J F, van der Meer W J. Earlier initiation of antibiotic treatment for severe infections after interventions to improve the organization and specific guidelines in the emergency department.  Arch Intern Med . 2000;  160 1317-1320
    CrossrefPubMedGoogle Scholar
  • 70 Marrie T J, Lau C Y, Wheeler S L, Wong C J, Vandervoort M K, Feagan B G. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-acquired pneumonia intervention trial assessing levofloxacin.  JAMA . 2000;  283 749-755
    CrossrefPubMedGoogle Scholar
  • 71 Moro M, Jepsen O, and the EURONIS Study Group. Infection control practices in intensive care units of 14 European countries.  Intensive Care Med . 1996;  22 872-879
    CrossrefPubMedGoogle Scholar
  • 72 Evans R S, Pestotnik S L, Classen D C, Clemmer T P, Weaver L K, Orme J F, Lloyd J F, Burke J P. A computer-assisted management program for antibiotics and other antiinfective agents.  New Engl J Med . 1998;  338 232-238
    Google Scholar
  • 73 Carlet J. Quality assessment of intensive care units.  Curr Opin Crit Care . 1996;  2 319-325
    PubMedGoogle Scholar
      >